{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T21:07:32Z","timestamp":1775855252864,"version":"3.50.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Internal Grant of Gebze Technical University","award":["BAP 2013-A-08"],"award-info":[{"award-number":["BAP 2013-A-08"]}]},{"DOI":"10.13039\/501100003356","name":"Scientific Research Grant by Gazi University","doi-asserted-by":"publisher","award":["02\/2009-21"],"award-info":[{"award-number":["02\/2009-21"]}],"id":[{"id":"10.13039\/501100003356","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Pyrazole derivatives are pharmacologically powerful agents pointing at new horizons in the development of anticancer therapies. In this study, anticarcinogenic potential of a series of pyrazole-acrylamide derivatives has been investigated in mesothelial, malignant mesothelioma and lung cancer cell lines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The effect of compounds on the viability of cells and the distribution of cell cycle were examined through MTS assay and PI staining, respectively. Apoptosis was evaluated via caspase-3 enzymatic assay and AO\/EB staining. Proteins involved in proliferation, survival and apoptosis were analysed by immunoblotting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Twelve compounds of 21 (4a\u20134v) reduced the viability of cells but, only the subset of five (4f, 4i, 4j, 4k and 4v) induced the caspase-3 activity. Among five, only one compound (4k) significantly suppressed phosphorylation and expression of ERK1\/2 and AKT proteins in 24 h. Exposing cancer cells to successive concentrations of 4k gave rise to dose- and time-dependent G2\/M phase arrest and apoptosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>4k has revealed its potent antiproliferative activity by decreasing viability and inhibiting proliferation and survival signals of cancer cells. Moreover, 4k has exposed cytostatic and apoptotic effect especially, on cancer cells. Therefore, it may be necessary to examine the biological actions of 4k in vivo as well.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.13012","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T09:53:20Z","timestamp":1536573200000},"page":"1619-1629","source":"Crossref","is-referenced-by-count":7,"title":["Investigation of potent anticarcinogenic activity of 1, 3-diarylpyrazole acrylamide derivatives <i>in vitro<\/i>"],"prefix":"10.1093","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6272-7158","authenticated-orcid":false,"given":"Asuman","family":"Demiroglu-Zergeroglu","sequence":"first","affiliation":[{"name":"Department of Molecular Biology & Genetics, Gebze Technical University , Gebze\/Kocaeli,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurettin","family":"Ayvali","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology & Genetics, Gebze Technical University , Gebze\/Kocaeli,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulseren","family":"Turhal","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology & Genetics, Gebze Technical University , Gebze\/Kocaeli,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hurmuz","family":"Ceylan","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology & Genetics, Gebze Technical University , Gebze\/Kocaeli,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sultan","family":"Nacak Baytas","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Gazi University , Ankara,","place":["Turkey"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,12,1]]},"reference":[{"key":"2024103012311647100_jphp13012-cit-0001","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1586\/17476348.2015.1081066","article-title":"Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies","volume":"9","author":"Bononi","year":"2015","journal-title":"Expert Rev Respir Med"},{"key":"2024103012311647100_jphp13012-cit-0002","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"2024103012311647100_jphp13012-cit-0003","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/02699050500284218","article-title":"The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions","volume":"24","author":"Yoon","year":"2006","journal-title":"Growth Factors"},{"key":"2024103012311647100_jphp13012-cit-0004","doi-asserted-by":"crossref","first-page":"a011254","DOI":"10.1101\/cshperspect.a011254","article-title":"MAP kinase pathways","volume":"4","author":"Morrison","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2024103012311647100_jphp13012-cit-0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrm3290","article-title":"PI3K signalling: the path to discovery and understanding","volume":"13","author":"Vanhaesebroeck","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2024103012311647100_jphp13012-cit-0006","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"2024103012311647100_jphp13012-cit-0007","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/370527a0","article-title":"Phosphatidylinositol-3-OH kinase direct target of Ras","volume":"370","author":"Rodriguez-Viciana","year":"1994","journal-title":"Nature"},{"key":"2024103012311647100_jphp13012-cit-0008","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/10799899909036639","article-title":"Regulation of protein kinase B","volume":"19","author":"Meier","year":"1999","journal-title":"J Recept Signal Transduct Res"},{"key":"2024103012311647100_jphp13012-cit-0009","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0898-6568(01)00271-6","article-title":"The protein kinase B\/Akt signalling pathway in human malignancy","volume":"14","author":"Nicholson","year":"2002","journal-title":"Cell Signal"},{"key":"2024103012311647100_jphp13012-cit-0010","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1053\/j.seminoncol.2015.09.023","article-title":"MEK1\/2 inhibitors: molecular activity and resistance mechanisms","volume":"42","author":"Wu","year":"2015","journal-title":"Semin Oncol"},{"key":"2024103012311647100_jphp13012-cit-0011","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrc4000","article-title":"MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road","volume":"15","author":"Caunt","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"2024103012311647100_jphp13012-cit-0012","doi-asserted-by":"crossref","first-page":"a031450","DOI":"10.1101\/cshperspect.a031450","article-title":"PI3K: a crucial piece in the RAS signaling puzzle","volume":"8","author":"Krygowska","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2024103012311647100_jphp13012-cit-0013","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1758834015571111","article-title":"MEK and PI3K inhibition in solid tumors: rationale and evidence to date","volume":"7","author":"Jokinen","year":"2015","journal-title":"Ther Adv Med Oncol"},{"key":"2024103012311647100_jphp13012-cit-0014","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/onc.2015.329","article-title":"Stamping out RAF and MEK1\/2 to inhibit the ERK1\/2 pathway: an emerging threat to anticancer therapy","volume":"35","author":"Mandal","year":"2016","journal-title":"Oncogene"},{"key":"2024103012311647100_jphp13012-cit-0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejmech.2016.01.012","article-title":"PI3K\/Akt\/mTOR and Ras\/Raf\/MEK\/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives","volume":"109","author":"Asati","year":"2016","journal-title":"Eur J Med Chem"},{"key":"2024103012311647100_jphp13012-cit-0016","first-page":"5334","article-title":"Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor","volume":"56","author":"Zanella","year":"1996","journal-title":"Cancer Res"},{"key":"2024103012311647100_jphp13012-cit-0017","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jtcvs.2004.11.029","article-title":"Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma","volume":"130","author":"Rascoe","year":"2005","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2024103012311647100_jphp13012-cit-0018","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1038\/sj.onc.1208744","article-title":"Human and mouse mesotheliomas exhibit elevated AKT\/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"key":"2024103012311647100_jphp13012-cit-0019","first-page":"181","article-title":"Activation of the PI3K-AKT pathway in human malignant mesothelioma cells","volume":"2","author":"Sekido","year":"2009","journal-title":"Mol Med Rep"},{"key":"2024103012311647100_jphp13012-cit-0020","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/carcin\/bgp097","article-title":"Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells","volume":"30","author":"Kawaguchi","year":"2009","journal-title":"Carcinogenesis"},{"key":"2024103012311647100_jphp13012-cit-0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1349-7006.2009.01336.x","article-title":"Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells","volume":"101","author":"Sekido","year":"2010","journal-title":"Cancer Sci"},{"key":"2024103012311647100_jphp13012-cit-0022","first-page":"203","article-title":"Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma","volume":"7","author":"Huang","year":"2017","journal-title":"Am J Cancer Res"},{"key":"2024103012311647100_jphp13012-cit-0023","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1002\/cbdv.200800354","article-title":"Antiproliferative and proapoptotic activities of a new class of pyrazole derivatives in HL-60 cells","volume":"6","author":"Anzaldi","year":"2009","journal-title":"Chem Biodivers"},{"key":"2024103012311647100_jphp13012-cit-0024","doi-asserted-by":"crossref","first-page":"5096","DOI":"10.1016\/j.bmc.2009.05.053","article-title":"Synthesis, antitumor evaluation, molecular modeling and quantitative structure-activity relationship (QSAR) of some novel arylazopyrazolodiazine and triazine analogs","volume":"17","author":"El-Shafei","year":"2009","journal-title":"Bioorganic Med Chem"},{"key":"2024103012311647100_jphp13012-cit-0025","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1016\/j.bmc.2009.09.004","article-title":"Synthesis and discovery of pyrazole-5-carbohydrazide N-glycosides as inducer of autophagy in A549 lung cancer cells","volume":"17","author":"Lian","year":"2009","journal-title":"Bioorganic Med Chem"},{"key":"2024103012311647100_jphp13012-cit-0026","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.ejmech.2009.11.050","article-title":"New pyrazoles incorporating pyrazolylpyrazole moiety: synthesis, anti-HCV and antitumor activity","volume":"45","author":"Riyadh","year":"2010","journal-title":"Eur J Med Chem"},{"key":"2024103012311647100_jphp13012-cit-0027","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1016\/j.bmcl.2010.06.121","article-title":"Synthesis of novel oxime-containing pyrazole derivatives and discovery of regulators for apoptosis and autophagy in A549 lung cancer cells","volume":"20","author":"Zheng","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"key":"2024103012311647100_jphp13012-cit-0028","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejmech.2009.09.046","article-title":"Synthesis, single-crystal characterization and preliminary biological evaluation of novel ferrocenyl pyrazolo[1,5-a]pyrazin-4(5H)-one derivatives","volume":"45","author":"Xie","year":"2010","journal-title":"Eur J Med Chem"},{"key":"2024103012311647100_jphp13012-cit-0029","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ejmech.2015.02.058","article-title":"Design, synthesis and biological evaluation of novel pyrazoline-containing derivatives as potential tubulin assembling inhibitors","volume":"94","author":"Qin","year":"2015","journal-title":"Eur J Med Chem"},{"key":"2024103012311647100_jphp13012-cit-0030","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3390\/molecules22030467","article-title":"Synthesis and evaluation of new pyrazoline derivatives as potential anticancer agents in HepG-2 cell line","volume":"22","author":"Xu","year":"2017","journal-title":"Molecules"},{"key":"2024103012311647100_jphp13012-cit-0031","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1007\/s00044-012-0317-2","article-title":"Synthesis of ester and amide derivatives of 1-phenyl-3-(thiophen-3-yl)-1H- pyrazole-4-carboxylic acid and study of their anticancer activity","volume":"22","author":"Inceler","year":"2013","journal-title":"Med Chem Res"},{"key":"2024103012311647100_jphp13012-cit-0032","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1007\/s00044-013-0505-8","article-title":"Synthesis, cytotoxicity, and molecular properties prediction of novel 1,3-diarylpyrazole derivatives","volume":"22","author":"Baytas","year":"2013","journal-title":"Med Chem Res"},{"key":"2024103012311647100_jphp13012-cit-0033","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejmech.2017.02.002","article-title":"Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics","volume":"129","author":"Hawash","year":"2017","journal-title":"Eur J Med Chem"},{"key":"2024103012311647100_jphp13012-cit-0034","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1007\/s00044-013-0580-x","article-title":"Novel 1,3-diarylpyrazole acrylamides: synthesis, antiplatelet activity screening, and in silico evaluation studies","volume":"22","author":"Baytas","year":"2013","journal-title":"Med Chem Res"},{"key":"2024103012311647100_jphp13012-cit-0035","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"2024103012311647100_jphp13012-cit-0036","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.1038\/onc.2008.297","article-title":"Caspases in apoptosis and beyond","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"2024103012311647100_jphp13012-cit-0037","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1021\/bc3003309","article-title":"Biomarkers and molecular probes for cell death imaging and targeted therapeutics","volume":"23","author":"Smith","year":"2012","journal-title":"Bioconjug Chem"},{"key":"2024103012311647100_jphp13012-cit-0038","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4161\/cbt.27311","article-title":"ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition","volume":"15","author":"Toulany","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"2024103012311647100_jphp13012-cit-0039","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.leu.2402824","article-title":"Involvement of PI3K\/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy","volume":"17","author":"Chang","year":"2003","journal-title":"Leukemia"},{"key":"2024103012311647100_jphp13012-cit-0040","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/15216540600957438","article-title":"ERK1\/2 MAP kinases in cell survival and apoptosis","volume":"58","author":"Lu","year":"2006","journal-title":"IUBMB Life"},{"key":"2024103012311647100_jphp13012-cit-0041","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","article-title":"Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases","volume":"24","author":"Morales","year":"2014","journal-title":"Crit Rev Eukaryot Gene Expr"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.13012","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/70\/12\/1619\/60223311\/jphp13012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/70\/12\/1619\/60223311\/jphp13012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T17:39:00Z","timestamp":1730309940000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/70\/12\/1619\/6121721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12,1]]},"published-print":{"date-parts":[[2018,12,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.13012","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12]]},"published":{"date-parts":[[2018,12,1]]}}}